Treatment with a soluble bone morphogenetic protein type 1A receptor (BMPR1A) fusion protein increases bone mass and bone formation in mice subjected to hindlimb unloading.
Cellular & Tissue Engineering
bone, protein, treatment, soluble, morphogenetic, type, receptor, bmpr1a, fusion, increases, bone, density, significantly, calcium, elevated, study, examining, treatment, soluble, morphogenetic, bone, study, examining, treatment, soluble, morphogenetic, protein, type, extended, spaceflight
bone, protein, treatment, soluble, morphogenetic, type, receptor, bmpr1a, fusion, increases
bone, study, examining, treatment, soluble, morphogenetic, protein, type, extended, spaceflight
bone, density, significantly, calcium, elevated, study, examining, treatment, soluble, morphogenetic
Study examining treatment with a soluble bone morphogenetic protein type. Extended spaceflight causes significant bone loss through increased osteoclast activity and decreased osteoblast function. Calcium metabolism is disrupted, with elevated resorption markers. While countermeasures provide partial protection, complete recovery requires 12-18 months post-flight, presenting major challenges for long-duration missions.
Study examining treatment with a soluble bone morphogenetic protein type. Bone mineral density decreased significantly during extended spaceflight missions. Osteoclast activity increased while osteoblast function declined. Calcium metabolism was disrupted with elevated urinary calcium excretion. Bone resorption markers TRAP and CTX-1 were significantly elevated. Mechanical loading countermeasures showed partial effectiveness. Recovery of bone density post-flight required 12-18 months on average.